CNS Pharmaceuticals Files 8-K on Shareholder Vote Matters

Ticker: CNSP · Form: 8-K · Filed: 2024-12-03T00:00:00.000Z

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

TL;DR

CNS Pharma had a shareholder vote on Nov 26th, details TBD.

AI Summary

On November 26, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report to disclose matters submitted to a vote of its security holders. The filing indicates a shareholder meeting or vote took place, but the specific details of the proposals or outcomes are not detailed in this initial report.

Why It Matters

This filing signals that CNS Pharmaceuticals has recently engaged its shareholders on important corporate decisions, which could impact the company's future direction and governance.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting on a shareholder vote, with no immediate financial or operational changes disclosed.

Key Players & Entities

FAQ

What specific matters were submitted for a vote by CNS Pharmaceuticals, Inc. security holders?

The 8-K filing states that matters were submitted to a vote of security holders, but does not specify the exact proposals or resolutions.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on November 26, 2024.

What is the filing date of this 8-K report?

The filing date of this 8-K report is December 3, 2024.

What is the principal executive office address for CNS Pharmaceuticals, Inc.?

The principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 786 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2024-12-02 19:34:16

Key Financial Figures

Filing Documents

07 Submission

Item 5.07 Submission of Matters to a Vote of Security Holders. CNS Pharmaceuticals, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting") at 9:30 a.m. MT at the Wells Fargo Center, 13th Floor - Uintah Boardroom, 299 S Main St, Salt Lake City, UT 84111. As of October 16, 2024 , the record date for the Special Meeting, there were 33,446,403 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Special Meeting, of which 11,310,361, or 33.82%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of Company common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Special Meeting. The proposals are described in detail in the Proxy Statement, the relevant portions of which are incorporated herein by reference. Proposal 1. Reverse Split Authorization Approval – The Company's stockholders granted the Company's Board of Directors authority, in its sole discretion, prior to the one-year anniversary of the Special Meeting, to effect a reverse stock split of the outstanding shares of the Company's common stock, at a reverse split ratio of between 1-for-2 and 1-for-50 as determined by the Board of Directors, by the following vote: Votes For Votes Against Abstain Broker Non-Votes 7,873,677 3,121,776 314,908 0 Proposal 2. Nasdaq Listing Rule 5635(d) Approval - For purposes of complying with Nasdaq Listing Rule 5635(d), the Company's stockholders approved the repricing of warrants issued to investors to purchase an aggregate of 2,434,120 shares of common stock with exercise prices ranging from $1.26 to $15.00 per share (the "Investor Warrants"), so that each of the Investor Warrants has a new exercise price equal to the lower of (i) $1.13 per share or (ii) the closing price of the Company common stock on the date when

View on Read The Filing